This will be a key presentation. I will have to more to say in a subsequent post about the data validation process utilized to finalize the MM Phase 2 trial data.
May 10, 2012
Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presented At 2nd European PostASCO Melanoma Meeting 2012 on June 22, 2012
The company issued a PR today regarding the June Euro postASCO conference.
This will be a key presentation. I will have to more to say in a subsequent post about the data validation process utilized to finalize the MM Phase 2 trial data.
This will be a key presentation. I will have to more to say in a subsequent post about the data validation process utilized to finalize the MM Phase 2 trial data.
No comments:
Post a Comment